Clinical and Experimental Nephrology

, Volume 15, Issue 5, pp 648–657

The pathogenesis and treatment of pediatric Henoch–Schönlein purpura nephritis

Review Article

Abstract

Henoch–Schönlein purpura (HSP) is a systemic disorder characterized by leukocytoclastic vasculitis involving the capillaries and the deposition of IgA immune complexes. Renal involvement is the principal cause of morbidity and mortality in children with HSP. Thus, it is important to clarify the onset mechanism of Henoch–Schönlein purpura nephritis (HSPN) and to identify the most appropriate treatment. We herein review the pathogenesis and treatment of HSPN. As to the pathogenesis, several studies suggest that galactose-deficient IgA1 is recognized by anti-glycan antibodies, leading to the formation of circulating immune complexes and their mesangial deposition, thereby inducing renal injury. Aggressive therapies for the treatment of severe HSPN, including multiple drug combination therapy and plasmapheresis, have been shown to be effective in ameliorating proteinuria and histological severity. Nevertheless, detailed investigations of the pathogenesis of HSPN and double-blind randomized control studies on children with HSPN are still necessary.

Keywords

HSP HSPN Pathogenesis Treatment Child Mizoribine Cyclophosphamide 

References

  1. 1.
    Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch–Schonlein purpura. Arthritis Rheum. 1990;33(8):1114–21.Google Scholar
  2. 2.
    Saulsbury FT. Epidemiology of Henoch-Schonlein purpura. Cleve Clin J Med. 2002;69:187–9.CrossRefGoogle Scholar
  3. 3.
    Bunchman TE, Mauer SM, Sibley RK, Vernier RL. Anaphylactoid purpura: characteristics of 16 patients who progressed to renal failure. Pediatr Nephrol. 1988;2:393–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Counahan R, Winterborn MH, White RH, Heaton JM, Meadow SR, Bluett NH, Swetschin H, Cameron JS, Chantler C. Prognosis of Henoch–Schönlein nephritis in children. Br Med J. 1977;2:11–4.Google Scholar
  5. 5.
    Yoshikawa N, Ito H, Yoshiya K, Nakahara C, Yoshiara S, Hasegawa O, Matsuyama S, Matsuo T. Henoch–Schoenlein nephritis and IgA nephropathy in children: a comparison of clinical course. Clin Nephrol. 1987;27:233–7.Google Scholar
  6. 6.
    Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch–Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360:1197–202.Google Scholar
  7. 7.
    Stewart M, Savage JM, Bell B, McCord B. Long term renal prognosis of Henoch–Schönlein purpura in unselected childhood population. Eur J Pediatr. 1988;147:113–5.Google Scholar
  8. 8.
    Nielsen HE. Epidemiology of Schonlein–Henoch purpura. Acta Paediatr Scand. 1988;77:125–31.Google Scholar
  9. 9.
    Kawasaki Y, Suyama K, Yugeta E, Katayose M, Suzuki S, Sakuma H, et al. The incidence and severity of Henoch–Schönlein purpura nephritis over a 22-year period in Fukushima Prefecture, Japan. Int Urol Nephrol. 2010;42:1023–9.Google Scholar
  10. 10.
    Vogler C, Eliason SC, Wood EG. Glomerular membranopathy in children with IgA nephropathy and Henoch–Schoenlein purpura. Pediatr Dev Pathol. 1999;2:227–35.Google Scholar
  11. 11.
    Kerr MA. The structure and function of human IgA. Biochem J. 1990;271:285–96.PubMedGoogle Scholar
  12. 12.
    Yoo EM, Morrison SL. IgA: an immune glycoprotein. Clin Immunol. 2005;116:3–10.PubMedCrossRefGoogle Scholar
  13. 13.
    Jones CL, Powell HR, Kincaid-Smith P, Roberton DM. Polymeric IgA and immune complex concentrations in IgA-related renal disease. Kidney Int. 1990;38:323–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Allen AC, Willis FR, Beattie TJ, Feehally J. Abnormal IgA glycosylation in Henoch–Schoenlein purpura restricted to patients with clinical nephritis. Nephrol Dial Transplant. 1998;13:930–4.Google Scholar
  15. 15.
    Egmond M, Damen CA, Spriel AB, Vidarsson G, Garderen E, Winkel JGJ. IgA and IgA Fc receptor. Trends Immunol. 2001;22:205–11.PubMedCrossRefGoogle Scholar
  16. 16.
    Moja P, Quesnel A, Resseguier V, Lambert C, Freycon F, Berthoux F, et al. Is there IgA from gut mucosal origin in the serum of children with Henoch–Schoenlein purpura? Clin Immunol Immunopathol. 1998;86:290–7.Google Scholar
  17. 17.
    Silva FG. IgA nephropathy and Henoch–Schoenlein syndrome. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall’s pathology of the kidney. 15th ed. Philadelphia: Lippincott-Raven; 1998. p. 479–540.Google Scholar
  18. 18.
    Allen A, Harper S, Feehally J. Origin and structure of pathogenic IgA in IgA nephropathy. Biochem Soc Trans. 1997;25:486–90.PubMedGoogle Scholar
  19. 19.
    Coppo R, Basolo B, Bulzomi MR, Roccatello D, Carbonara AO, Barbiano di Belgiojoso G, et al. IgA1 and IgA2 immune complexes in primary IgA nephropathy and Henoch–Schoenlein purpura nephritis. Clin Exp Immunol. 1984;57:583–90.Google Scholar
  20. 20.
    Levinsky RJ, Barratt TM. IgA immune complexes in Henoch–Schoenlein purpura. Lancet. 1979;24:1100–3.Google Scholar
  21. 21.
    Leu KK, Wyatt RJ, Moldoveanu Z, Tomana M, Julian BA, Hogg RJ, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch–Schoenlein purpura. Pediatr Nephrol. 2007;22:2067–72.Google Scholar
  22. 22.
    Oortwijn BD, Eijgenraam JW, Rastaldi MP, Roos A, Daha MR, van Kooten C. The role of secretary IgA and complement in IgA nephropathy. Semin Nephrol. 2008;28:58–65.PubMedCrossRefGoogle Scholar
  23. 23.
    Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M. Complement activation through the lectin pathway in patients with Henoch–Schönlein purpura nephritis. Am J Kidney Dis. 2000;35:401–7.Google Scholar
  24. 24.
    Hisano S, Matsushita M, Fujita T, Iwasaki H. Activation of the lectin complement pathway in Henoch–Schönlein purpura nephritis. Am J Kidney Dis. 2005;45:295–302.Google Scholar
  25. 25.
    Moura IC, Benhamou M, Launay P, Vrtovsnik F, Blank U, Monteiro RC. The glomerular response to IgA deposition in IgA nephropathy. Semin Nephrol. 2008;28:88–95.PubMedCrossRefGoogle Scholar
  26. 26.
    Kawasaki Y, Suzuki J, Nemoto K, Nozawa R, Suzuki S, Suzuki H. Clinical and pathological features of children with Henoch–Schoenlein purpura nephritis: risk factors associated with poor prognosis. Clin Nephrol. 2003;60:153–60.Google Scholar
  27. 27.
    Fujieda M, Oishi N, Naruse K, Hashizume M, Nishiya K, Kurashige T, Ito K. Soluble thrombomodulin and antibodies to bovine glomerular endothelial cells in patients with Henoch–Schoenlein purpura. Arch Dis Child. 1998;78:240–4.Google Scholar
  28. 28.
    Kawasaki Y, Suzuki J, Nozawa R, Sakai N, Tannji M, Isome M, et al. FB21, a monoclonal antibody that reacts with a sialic-acid-dependent carbohydrate epitope, is a marker for glomerular endothelial cell injury. Am J Kidney Dis. 2004;44:239–49.PubMedCrossRefGoogle Scholar
  29. 29.
    Masuda M, Nakanishi K, Yoshizawa N, Iijima K, Yoshikawa N. Group A streptococcal antigen in the glomeruli of children with Henoch–Schönlein nephritis. Am J Kidney Dis. 2003;41:366–70.Google Scholar
  30. 30.
    Davin JC, Pierard G, Dechenne C, Grossman D, Nagy J, Quacoe M, et al. Possible pathogenic role of IgE in Henoch–Schönlein purpura. Pediatr Nephrol. 1994;8:169–71.Google Scholar
  31. 31.
    Ehara T, Shigematsu H. Mast cells in the kidney. Nephrology (Carlton). 2003;8:130–8.CrossRefGoogle Scholar
  32. 32.
    Namgoong MK, Lim BK, Kim JS. Eosinophil cationic protein in Henoch–Schönlein purpura and in IgA nephropathy. Pediatr Nephrol. 1997;11:703–6.Google Scholar
  33. 33.
    Kawasaki Y, Hosoya M, Suzuki H. Possible pathologenic role of interleukin-5 and eosino cationic protein in Henoch–Schönlein purpura nephritis. Pediatr Int. 2005;47:51251–7.Google Scholar
  34. 34.
    Kawasaki Y, Imaizumi T, Matsuura H, Ohara S, Takano K, Suyama K, et al. Renal expression of alpha-smooth muscle actin and c-Met in children with Henoch–Schönlein purpura nephritis. Pediatr Nephrol. 2008;23:913–9.Google Scholar
  35. 35.
    Algoet C, Proesmans W. Renal biopsy 2–9 years after Henoch–Schönlein purpura. Pediatr Nephrol. 2003;18:471–3.Google Scholar
  36. 36.
    Goldstein AR, White RH, Akuse R, Chantler C. Long-term follow-up of childhood Henoch–Schoenlein nephritis. Lancet. 1992;339:280–2.Google Scholar
  37. 37.
    Meadow SR, Glasgow EF, White RH, Moncrieff MW, Cameron JS, Ogg CS. Schoenlein–Henoch nephritis. Q J Med. 1972;41:241–5.Google Scholar
  38. 38.
    Reif S, Jain A, Santiago J, Rossi T. Protein-losing enteropathy as a manifestation of Henoch–Schoenlein purpura. Acta Paediatr Scand. 1991;80:482–5.Google Scholar
  39. 39.
    Cull DL, Rosario V, Lally KP, Ratner I, Mahour GH. Surgical implications of Henoch–Schoenlein purpura. J Pediatr Surg. 1990;25:741–3.Google Scholar
  40. 40.
    Kawasaki Y, Suzuki H. Henoch–Schoenlein nephritis. In: Geary DF, Schaefer F, editors. Comprehensive pediatric nephrology. Mosby: Elsevier; 2008. p. 343–51.Google Scholar
  41. 41.
    Suthanthiran M, Strom TB. Immunoregulatory drugs: mechanistic basis for use in organ transplantation. Pediatr Nephrol. 1997;11:651–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Taube D, Brown Z, Williams DG. Long-term impairment of suppressor-cell function by cyclophosphamide in minimal-change nephropathy and its association with therapeutic response. Lancet. 1981;1:235–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K. Studies on bredinin. I. Isolation, characterization and biological properties. J Antibiot. 1974;27:775–82.PubMedGoogle Scholar
  44. 44.
    Ichikawa Y, Ihara H, Takahara S. The immunosuppressive mode of action of mizoribine. Transplantation. 1984;38:262–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem. 1999;6:575–97.PubMedGoogle Scholar
  46. 46.
    Kawasaki Y. Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol. 2009;681482.Google Scholar
  47. 47.
    Diasio RB, Lo Buglio AF. Immunomodulators: immunosuppressive agents and immunostimulants. In: Hardman JG, editor. Goodman and Gilman’s: The pharmacological basis of therapeutics. 9th ed, vol. 52. New York: McGraw-Hill; 1996. p. 1291–308.Google Scholar
  48. 48.
    Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schoenlein–Henoch purpura nephritis. Pediatr Nephrol. 1998;12:238–43.Google Scholar
  49. 49.
    Mollica F, Li Volti S, Garozzo R, Russo G. Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura. Eur J Pediatr. 1992;151:140–4.PubMedCrossRefGoogle Scholar
  50. 50.
    Kawasaki Y, Suzuki J, Nozawa R, Suzuki S, Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy for severe Henoch–Schoenlein nephritis. Pediatrics. 2003;111:785–9.Google Scholar
  51. 51.
    Oner A, Tinaztepe K, Erdogan O. The effect of triple therapy on rapidly progressive type of Henoch–Schönlein nephritis. Pediatr Nephrol. 1995;9(1):6–10.Google Scholar
  52. 52.
    Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch–Schoenlein purpura nephritis to corticosteroid and azathioprine therapy. Clin Nephrol. 1998;49:9–14.Google Scholar
  53. 53.
    Iijima K, Ito-Kariya S, Nakamura H, Yoshikawa N. Multiple combined therapy for severe Henoch–Schoenlein nephritis in children. Pediatr Nephrol. 1998;12:244–8.Google Scholar
  54. 54.
    Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman A. Treatment of Henoch–Schoenlein purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol. 2001;21:128–33.Google Scholar
  55. 55.
    Kawasaki Y, Suzuki J, Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch–Schoenlein nephritis: a clinical and histopathological study. Nephrol Dial Transplant. 2004;19:858–64.Google Scholar
  56. 56.
    Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Jeong HJ. Henoch–Schönlein purpura nephritis with nephrotic-range proteinuria: histological regression possibly associated with cyclosporin A and steroid treatment. Scand J Rheumatol. 2005;34:392–5.Google Scholar
  57. 57.
    Kawasaki Y, Suyama K, Hashimoto K, Hosoya M. Methylprednisolone pulse plus mizoribine in children with Henoch–Schoenlein purpura nephritis. Clin Rheumatol. 2011;30:529–35.Google Scholar
  58. 58.
    Hattori M, Ito K, Konomoto T, Kawaguchi H, Yoshioka T, Khono M. Plasmapheresis as the sole therapy for rapidly progressive Schoenlein–Henoch purpura nephritis in children. Am J Kidney Dis. 1999;33:427–33.Google Scholar
  59. 59.
    Kawasaki Y, Suzuki J, Murai M, Takahashi A, Isome M, Nozawa R, et al. Plasmapheresis therapy for rapidly progressive Henoch–Schoenlein nephritis. Pediatr Nephrol. 2004;19:920–3.Google Scholar
  60. 60.
    Heldrich FJ, Minkin S, Gatdula CI. Intravenous immunoglobulin in Henoch–Schoenlein purpura: a case study. Md Med J. 1993;42:577–9.Google Scholar
  61. 61.
    Suguyama H, Watanabe N, Onoda T, Kikumoto Y, Yamamoto M, Maeta M, et al. Successful treatment of progressive Henoch–Schoenlein purpura nephritis with tonsillectomy and steroid pulse therapy. Intern Med. 2005;44:611–5.Google Scholar
  62. 62.
    Kawasaki Y, Suyama K, Matsumoto A, Takano K, Hashimoto K, Suzuki S, et al. Efficacy of tonsillectomy plus methylprednisolone pulse therapy for a child with Henoch–Schoenlein purpura nephritis. Tohoku J Exp Med. 2007;211:291–5.Google Scholar
  63. 63.
    Meulders Q, Pirson Y, Cosyns JP, Squifflet JP, de Strihou C. Course of Henoch–Schoenlein nephritis after renal transplantation: report on ten patients and review of the literature. Transplantation. 1994;58:1179–86.Google Scholar
  64. 64.
    Ramos EL. Recurrent diseases in the renal allograft. J Am Soc Nephrol. 1991;2:109–21.PubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2011

Authors and Affiliations

  1. 1.Department of PediatricsFukushima Medical University School of MedicineFukushimaJapan

Personalised recommendations